CDXS
NASDAQ
US
Codexis, Inc. - Common Stock
$1.82
▲ +$0.08
(+4.60%)
Vol 778K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$147.2M
ROE
-121.4%
Margin
-120.8%
D/E
103.07
Beta
2.47
52W
$2–$6
Wall Street Consensus
13 analysts · Apr 20264
Strong Buy
6
Buy
3
Hold
0
Sell
0
Strong Sell
76.9%
Buy Rating
Price Chart
Similar Stocks
OABI
OmniAb Inc
$266.3M
ATLN
Atlantic International Corp
$77.8M
QTRX
Quanterix Corp
$297.1M
TKNO
Alpha Teknova Inc
$203.4M
QSI
Quantum-Si Inc
$237.0M
LFCR
Lifecore Biomedical Inc
$306.5M
SEER
Seer Inc
$102.1M
RPID
Rapid Micro Biosystems Inc
$128.5M
CSBR
Champions Oncology Inc
P/E 32.5
$96.0M
MXCT
MaxCyte Inc
$165.3M
Earnings
Beat rate: 40.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.04 | $0.11 | +$0.15 |
| Sep 2025 | $-0.15 | $-0.22 | $-0.07 |
| Jun 2025 | $-0.19 | $-0.16 | +$0.03 |
| Mar 2025 | $-0.24 | $-0.25 | $-0.01 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $21.5M | $7.5M | $15.3M | $8.6M | $38.9M |
| Net Income | — | -$10.4M | -$20.7M | -$13.3M | -$19.6M | $9.6M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -105.8% | -118.5% | -105.8% | -105.8% | -121.4% | -121.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -86.6% | -149.5% | -113.7% | -113.7% | -120.8% | -120.8% |
| Gross Margin | 86.3% | 71.6% | 77.6% | 77.6% | 79.3% | 79.3% |
| D/E Ratio | 70.78 | 58.81 | 70.78 | 70.78 | 103.07 | 103.07 |
| Current Ratio | 5.82 | 3.72 | 5.82 | 5.82 | 4.12 | 4.12 |
Key Ratios
ROA (TTM)
-47.4%
P/S (TTM)
2.78
P/B
5.8
EPS (TTM)
$-0.75
CF/Share
$-1.13
Rev Growth 3Y
-17.3%
52W High
$5.51
52W Low
$1.52
$1.52
52-Week Range
$5.51
Financial Health
Free Cash Flow
$19.6M
Net Debt
$22.4M
Cash
$50.8M
Total Debt
$73.2M
As of Dec 31, 2025
How does CDXS compare to Life Sciences Tools & Services peers?
Peer group: Micro-cap Life Sciences Tools & Services (All) · 44 companies
CDXS valuation vs Life Sciences Tools & Services peers
P/E ratio
—
▼
0%
below
peers
(32.5)
vs Peers
vs Industry
Undervalued
P/S ratio
2.8
▼
26%
below
peers
(3.7)
vs Peers
vs Industry
Pricier
P/B ratio
5.8
▲
194%
above
peers
(2.0)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.5%)
vs Peers
vs Industry
Low yield
CDXS profitability vs Life Sciences Tools & Services peers
ROE
-121.4%
▼
392%
below
peers
(-24.7%)
vs Peers
vs Industry
Weak
Net margin
-120.8%
▼
334%
below
peers
(-27.8%)
vs Peers
vs Industry
Weak
Gross margin
79.3%
▲
64%
above
peers
(48.2%)
vs Peers
vs Industry
Top tier
ROA
-47.4%
▼
225%
below
peers
(-14.6%)
vs Peers
vs Industry
Weak
CDXS financial health vs Life Sciences Tools & Services peers
D/E ratio
103.1
▲
345%
above
peers
(23.2)
vs Peers
vs Industry
High debt
Current ratio
4.1
▲
24%
above
peers
(3.3)
vs Peers
vs Industry
Below avg
Beta
2.5
▲
79%
above
peers
(1.4)
vs Peers
vs Industry
More volatile
CDXS fundamentals radar
CDXS
Peer median
Industry
CDXS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CDXS vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
LUTZ STEFAN
Officer · Feb 24
5862 shs
ERBEZ GEORGIA L
Chief Financial Officer · Feb 06
3826 shs
MOORE ALISON
Chief Executive Officer · Feb 06
3826 shs
LUTZ STEFAN
Officer · Feb 06
2492 shs
LUTZ STEFAN
Officer · Jan 07
4685 shs
Last 90 days
Top Holders
Top 5: 34.21%Aberdeen Group plc
8.77%
$12.6M
Blackrock Inc.
8.14%
$11.7M
Opaleye Management Inc.
7.47%
$10.7M
Vanguard Group Inc
5.44%
$7.8M
Nantahala Capital Managemen…
4.39%
$6.3M
As of Dec 31, 2025
Latest News
No related news yet